📊 Stem Cell Therapy Statistics at a Glance
Stem cell medicine is considerably more advanced in some areas than many patients realize, but much less established in others.
🎯 What Is the Success Rate of Stem Cell Therapy?
The most accurate answer is that there is no scientifically valid universal success rate for stem cell therapy.
A provider might advertise an “80% success rate,” but that number means very little unless you know what success actually means.
Was it less pain? Better mobility? MRI changes? Insulin independence? Neurological improvement? Patient satisfaction?
Any meaningful outcome must refer to a specific treatment, patient population, medical condition, and clinical outcome.
Two patients can both describe a treatment as successful while meaning completely different things.
One person may consider a knee treatment successful because their pain decreased enough to return to exercise.
Another patient undergoing hematopoietic stem cell transplantation may define success as remaining free from disease progression.
Those outcomes cannot reasonably be combined into a single percentage.
Stem cell treatment outcomes can depend on:
- the condition being treated
- disease severity and duration
- age and general health
- cell type and source
- autologous versus donor-derived cells
- cell manufacturing and processing
- dose and viability
- route of administration
- accompanying therapies or rehabilitation
- the clinical endpoint being measured
- length of follow-up
Even within randomized knee osteoarthritis research, studies have used different cell sources, doses, preparation methods, and outcome measures. That makes broad comparisons difficult.⁶
🔬 How Much Stem Cell Research Has Reached Human Trials?
Stem cell research has progressed far beyond laboratory experiments.
A comprehensive 2026 review identified more than 8,200 interventional study records containing the term “stem cells” on ClinicalTrials.gov as of November 2024.¹
That is an impressive number, but it requires context.
A registered clinical trial does not mean that the therapy has been proven effective. Trials can be designed to assess:
- safety
- dosing
- biological activity
- feasibility
- preliminary efficacy
- comparison with placebo or standard treatment
Many treatments never progress from early-stage research to regulatory approval.
🧬 What about iPSC and pluripotent stem cell therapies?
Human pluripotent stem cell research provides another indication of how quickly the field is evolving.
A 2025 Cell Stem Cell analysis identified 83 human pluripotent stem cell-derived products being investigated across 116 regulator-approved clinical trials worldwide as of December 2024.⁵
These therapies are particularly interesting because pluripotent cells can be directed toward highly specialized cell types.
Researchers are investigating approaches involving:
- dopamine-producing neurons
- pancreatic islet cells
- retinal cells
- neural progenitor cells
- cardiomyocytes
- other disease-specific cell products
This represents an important shift.
Rather than using the same generic cell infusion for unrelated diseases, some of the most advanced regenerative therapies are being designed around specific biological deficits.
✅ How Many Stem Cell Therapies Are Actually Approved?
Clinical research and regulatory approval are very different milestones.
A 2026 international review identified 37 stem cell products approved as drugs within their respective jurisdictions.
Most were based on hematopoietic stem cells or mesenchymal stromal cells.¹
One major U.S. milestone occurred in December 2024 when the FDA approved Ryoncil (remestemcel-L-rknd).
Ryoncil became the first FDA-approved mesenchymal stromal cell therapy and is indicated for steroid-refractory acute graft-versus-host disease in certain pediatric patients.²
That approval is important, but it should not be misunderstood.
This distinction matters when clinics refer broadly to published MSC research as evidence for their own treatment protocols.
🏥 Some Stem Cell Therapies Are Already Established Medicine
Stem cell therapy is often associated with experimental regenerative clinics, but hematopoietic stem cell transplantation tells a very different story.
In the United States, 22,579 hematopoietic cell transplants were reported in 2024.³
Across the European Society for Blood and Marrow Transplantation network, 47,204 HCT procedures were reported in 43,791 patients in 2024.
The EBMT survey has now recorded more than one million HCT procedures since 1990.⁴
Hematopoietic stem cell transplantation has established clinical roles in selected:
- leukemias
- lymphomas
- multiple myeloma
- bone marrow failure disorders
- immune and hematologic diseases
This is why broad statements such as “stem cells are proven” or “stem cells are experimental” are both misleading.
Some stem cell therapies are standard medicine. Others remain early-stage research.
📈 What Do Stem Cell Therapy Results Look Like by Condition?
The usefulness of stem cell success rates becomes much clearer when the evidence is separated by medical condition.
🦵 What Is the Stem Cell Therapy Success Rate for Knee Osteoarthritis?
Knee osteoarthritis is one of the most commonly marketed regenerative medicine applications and one of the better studied.
A 2025 Cochrane review included 25 randomized trials involving 1,341 participants.⁶
In placebo-controlled studies, stem cell treatment produced an estimated:
- 1.2-point greater improvement in pain on a 0 to 10 scale
- 14.2-point greater improvement in function on a 0 to 100 scale
at approximately six months.⁶
Those findings are encouraging, but the evidence for pain and function was rated low certainty.
Cell sources, preparation methods, doses, and protocols differed substantially between studies.
Researchers also remained uncertain about several longer-term outcomes.⁶
Most importantly, symptom improvement should not automatically be interpreted as structural regeneration.
Current evidence suggests some patients may experience improvements in pain and function.
It does not establish predictable cartilage regrowth or a universal knee stem cell success rate.
🔗 Read more → Best Countries for Stem Cell Therapy for Orthopedic Conditions
🧠 What Does the Evidence Show for Multiple Sclerosis?
Multiple sclerosis illustrates how differently stem cells can be used.
A 2025 ECTRIMS/EBMT consensus statement describes autologous hematopoietic stem cell transplantation (AHSCT) as a treatment option for selected patients with relapsing MS that is refractory to disease-modifying treatment.⁷
The objective is not simply to inject regenerative cells into damaged nervous tissue.
AHSCT uses intensive treatment to suppress or eliminate much of the dysfunctional immune repertoire.
The patient's hematopoietic stem cells then help reconstitute the immune system.
Patient selection is therefore crucial.
Age, disease subtype, inflammatory activity, disability level, previous treatments, and overall health can all influence both potential benefit and risk.⁷
This is also why AHSCT outcomes should not be used to justify unrelated MSC therapies marketed for neurological regeneration.
🩸 Can Stem Cells Treat Type 1 Diabetes?
One of the most striking recent advances has come from stem cell-derived pancreatic islet cells.
In a 2025 Phase I/II study published in The New England Journal of Medicine, 10 of 12 full-dose recipients, or approximately 83%, were insulin-independent one year after receiving the stem cell-derived islet therapy zimislecel.⁸
This is significant because the therapy is designed to replace a very specific lost biological function: insulin production.
However, the result should still be interpreted cautiously.
The cohort was small, participants received immunosuppressive therapy, and longer-term durability remains under investigation.⁸
🧠 Can Stem Cells Treat Parkinson's Disease?
Stem cell-derived therapy is also beginning to produce human data in Parkinson's disease.
In a 2025 Phase I/II trial in Japan, seven patients aged 50 to 69 received bilateral transplantation of iPSC-derived dopaminergic progenitor cells and were followed for 24 months.⁹
Researchers reported:
- no serious adverse events requiring hospitalization or resulting in death
- no tumor-like graft overgrowth
- evidence of dopamine-related biological activity
- exploratory motor improvements in several participants
Among six patients included in the efficacy analysis, four improved on motor scores when assessed off medication and five improved when assessed on medication.⁹
These results are promising.
But seven patients in an early open-label trial cannot establish a reliable Parkinson's stem cell therapy success rate.
The appropriate conclusion is that the treatment has demonstrated early biological and clinical potential and now requires larger controlled studies.
♿ Can Stem Cells Repair Spinal Cord Injuries?
Spinal cord injury provides one of the clearest examples of why headline percentages can be misleading.
A 2026 Nature Medicine Phase I trial treated 4 people with subacute complete cervical spinal cord injury using iPSC-derived neural stem/progenitor cells.¹⁰
During approximately two to four years of follow-up:
- no tumor formation was observed
- no graft-related adverse events were reported
- the median neurological motor-score improvement at 52 weeks was 13 points
- two patients improved in AIS classification¹⁰
It would be tempting to describe that as a “50% success rate” because two of the 4 patients improved in AIS grade.
That would be scientifically inappropriate.
The trial involved only 4 people, had no control group, and was designed primarily to evaluate safety.
🛡️ Is Stem Cell Therapy Safe?
Stem cell therapy does not have one universal safety profile.
Risk depends on the cell product, manufacturing process, route of administration, patient health, disease being treated, dose, and any associated procedures.
One useful data point comes from a 2026 systematic review and meta-analysis examining 42 randomized controlled trials involving 2,280 patients receiving intravascular umbilical cord-derived MSCs.¹¹
UC-MSC administration was associated with an increased risk of fever.
However, researchers did not identify a clear harm signal across several other predefined outcomes, including infection, death, malignancy or ectopic tissue formation, and thrombotic events.
None of the included trials were stopped early because of safety concerns.¹¹
That is reassuring for the specific type of treatment evaluated.
It does not demonstrate that every MSC product, dose, treatment route, or clinic protocol carries the same risk.
Commercial availability also should not be mistaken for clinical validation.
The ISSCR recommends that unproven stem cell interventions generally remain within appropriately regulated clinical research or tightly controlled medical innovation pathways.¹²
The FDA has likewise continued to warn consumers about unapproved human cell and tissue products marketed for a wide range of conditions.¹³
🔗 Read more → Stem Cell Therapy in Thailand: Costs, Clinics, Safety & What to Know
🧭 How Should You Evaluate a Stem Cell Clinic's Success Rate?
If a clinic tells you its treatment has an 80%, 90%, or even higher success rate, the percentage should be the beginning of your questions, not the end.
1. What exactly counts as success?
Was success defined as:
- lower pain
- better mobility
- MRI changes
- neurological improvement
- lower medication use
- avoiding surgery
- patient satisfaction
Without a clear endpoint, the percentage has limited meaning.
2. How many patients produced the statistic?
Eight successes among ten patients and 800 successes among 1,000 patients can both be reported as 80%.
They provide very different levels of confidence.
3. Was there a control group?
Without an appropriate comparator, it can be difficult to separate the treatment effect from rehabilitation, natural recovery, placebo or contextual effects, and other simultaneous treatments.
4. Was the research performed using the same cell product?
Evidence for one MSC preparation should not automatically validate another.
Ask about:
- cell source
- manufacturing
- viability
- dose
- passage or expansion
- administration route
- accompanying therapies
5. Were the patients similar to you?
Disease severity matters.
Evidence involving early-stage osteoarthritis, for example, may not tell you how the same treatment performs in severe end-stage disease.
6. How long were patients followed?
Improvement after six weeks is not the same as improvement that remains at one, three, or five years.
7. Can you see the evidence?
Important claims should ideally connect to:
- peer-reviewed research
- registered clinical trials
- transparent internal outcome data
- identifiable investigators
- clear adverse-event reporting
✅ Key Takeaways: Outcomes in Stem Cell Therapy
The most important thing to understand about stem cell therapy success rates is that the science is highly condition-specific.
Hematopoietic stem cell transplantation is already established medicine for selected conditions.
MSC therapies have accumulated substantial clinical research, but evidence varies widely by indication.
Knee osteoarthritis trials suggest possible improvements in pain and function.
While stem cell-derived therapies for type 1 diabetes, Parkinson's disease, and spinal cord injury are producing exciting human data but remain at earlier stages of development.¹⁻¹¹
For patients considering treatment, that changes the decision-making process.
Instead of asking:
“Do stem cells work?”
Ask:
“What evidence supports this exact cell product, treatment protocol, and delivery method for someone with my condition and disease severity?”
That is a more difficult question.
It is also the one that can help you make a more informed decision.
🧭 Making Sense of the Evidence Before Choosing Treatment
Stem cell medicine is evolving quickly enough that the evidence for a condition can change as new trials are published.
At the same time, the gap between promising scientific research and commercially available treatment remains one of the hardest things for patients to navigate.
If you are considering stem cell therapy, especially treatment abroad, compare more than cell counts and advertised success rates.
Look at the:
- evidence for your specific condition
- cell product being offered
- physician's experience
- treatment strategy
- manufacturing and quality controls
- delivery method
- rehabilitation plan
- follow-up process
STEMCIERGE exists to help patients understand those differences and compare regenerative medicine options more objectively before committing to treatment.
❓ Frequently Asked Questions
What is the average success rate of stem cell therapy?
There is no scientifically accepted average success rate for stem cell therapy. Outcomes differ according to the disease, cell type, treatment protocol, patient population, and definition of success. Combining unrelated stem cell treatments into one percentage would be misleading.¹
How many stem cell clinical trials are there?
A 2026 review found more than 8,200 interventional study records containing “stem cells” on ClinicalTrials.gov as of November 2024.¹ This reflects the scale of research activity, not 8,200 proven therapies.
Are any stem cell therapies FDA approved?
Yes, specific stem-cell-based therapies are approved for defined indications. In December 2024, the FDA approved Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in certain pediatric patients.²
Does stem cell therapy work for knee osteoarthritis?
A 2025 Cochrane review found low-certainty evidence that stem cell injections may improve knee osteoarthritis pain and function compared with placebo.⁶ Current evidence does not establish a universal success rate or predictable cartilage regeneration.
Can stem cells repair spinal cord injuries?
Stem cell therapy for spinal cord injury remains experimental. A four-person Phase I trial published in 2026 reported encouraging neurological changes and no tumor formation or graft-related adverse events during follow-up, but the study was too small and was not designed to establish efficacy.¹⁰
Is stem cell therapy safe?
Safety depends on the cell product, manufacturing process, administration route, medical condition, and patient. A 2026 analysis of 42 randomized trials involving UC-MSCs found an increased risk of fever but no clear harm signal across several other predefined outcomes.¹¹ These findings cannot automatically be generalized to other stem cell treatments.
Are stem cells proven for anti-aging?
Stem cell biology is closely connected to aging research, but there is currently insufficient clinical evidence to establish that commercial stem cell infusions reverse biological aging, extend lifespan, or produce reliable whole-body rejuvenation.
Why do stem cell clinics report different success rates?
Clinics may use different definitions of success, patient populations, treatment protocols, follow-up periods, and outcome measures. Two providers can therefore advertise very different percentages without necessarily measuring the same thing.
📚 References
¹ Chen S, et al. Clinical translational research on stem cell products: prospects and challenges. Signal Transduction and Targeted Therapy. 2026.
² U.S. Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-Refractory Acute Graft-Versus-Host Disease. December 18, 2024.
³ Health Resources and Services Administration. Donation and Transplantation Statistics: Blood Stem Cell. Updated 2026.
⁴ Greco R, et al. The 2024 EBMT activity report: crossing one million HCTs. Bone Marrow Transplantation. 2026.
⁵ Kirkeby A, Main H, Carpenter M. Pluripotent stem-cell-derived therapies in clinical trial: a 2025 update. Cell Stem Cell. 2025;32:10–37.
⁶ Whittle SL, et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews. 2025.
⁷ Muraro PA, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder: recommendations from ECTRIMS and the EBMT. Nature Reviews Neurology. 2025;21:140–158.
⁸ Reichman TW, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. New England Journal of Medicine. 2025;393:858–868.
⁹ Sawamoto N, et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease. Nature. 2025;641:971–977.
¹⁰ Sugai K, et al. An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up. Nature Medicine. 2026.
¹¹ Hum C, et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine. 2026.
¹² International Society for Stem Cell Research. Guidelines for Stem Cell Research and Clinical Translation. 2025 update.
¹³ U.S. Food and Drug Administration. Patient and Consumer Warning about Potential Serious Risks Following Use of Unapproved Human Cell and Tissue Products. May 2026.
